Equities
Health CareMedical Equipment and Services
  • Price (USD)114.69
  • Today's Change-1.90 / -1.63%
  • Shares traded2.56m
  • 1 Year change-9.58%
  • Beta1.0421
Data delayed at least 15 minutes, as of Jun 08 2023 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets business offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics businesses are comprised of six areas of activity, providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. Its product categories include liquid chromatography systems and components and liquid chromatography mass spectrometry systems.

  • Revenue in USD (TTM)7.04bn
  • Net income in USD1.35bn
  • Incorporated1999
  • Employees18.40k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 345-8296
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
announced
Transaction
value
E-Msion IncDeal completed09 Mar 202309 Mar 2023Deal completed-18.60%--
Avida Biomed IncDeal completed04 Jan 202304 Jan 2023Deal completed-23.56%--
PSS Polymer Standards Service GmbHDeal completed02 Aug 202202 Aug 2022Deal completed-14.04%--
Data delayed at least 15 minutes, as of Jun 08 2023 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fortive Corp5.91bn763.70m24.33bn18.00k32.242.4619.874.122.132.1316.5227.920.36864.436.32328,327.804.764.685.685.7857.8656.6812.9214.790.71679.410.238614.3710.870.240730.27-1.50-2.920.00
Keysight Technologies Inc5.59bn1.18bn28.80bn15.00k24.716.1020.595.156.546.5430.9726.460.67872.296.71372,666.7014.339.9617.2412.0464.0360.1721.1115.072.6860.250.27590.009.6911.1925.7361.6020.77--
Mettler-Toledo International Inc3.95bn886.93m29.23bn16.40k33.71--29.207.4039.3839.38175.40-1.111.173.706.28240,893.7026.2222.8037.9532.6459.1058.2422.4519.930.855618.591.010.005.437.5413.4614.26-0.9902--
Illumina, Inc.4.45bn-4.49bn31.99bn11.50k--4.78--7.19-28.58-28.5828.2842.360.32843.116.78386,695.70-33.13-2.62-38.41-3.0863.2168.12-100.90-6.261.161.200.2504--1.2810.74-677.95--8.35--
Agilent Technologies Inc7.04bn1.35bn34.44bn18.40k25.675.9520.974.894.544.5423.6619.600.66273.135.34388,950.3012.7210.7115.2112.8754.5954.1019.1917.921.7127.950.32121.578.378.903.6412.8910.5810.03
AMETEK, Inc.6.29bn1.19bn34.83bn19.60k29.284.4922.975.545.165.1627.2233.660.51164.116.33320,873.609.709.1411.0710.5235.1435.8018.9717.721.0718.450.224517.3810.897.4217.1214.4713.1119.57
Roper Technologies Inc5.56bn1.03bn48.03bn15.80k46.592.9428.128.649.6726.2852.05153.230.210810.626.97352,006.303.924.954.455.6069.6667.9518.5820.850.76288.800.289821.9611.133.1222.395.443.3812.12
Emerson Electric Co17.49bn2.52bn48.14bn85.50k19.714.2413.112.754.278.1429.7619.880.5334.366.02204,608.207.5810.2611.3114.4644.7942.0814.2313.170.920814.980.368751.467.645.1640.3014.482.211.42
Data as of Jun 08 2023. Currency figures normalised to Agilent Technologies Inc's reporting currency: US Dollar USD

Institutional shareholders

36.76%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202324.21m8.19%
BlackRock Fund Advisorsas of 31 Mar 202316.60m5.62%
SSgA Funds Management, Inc.as of 31 Mar 202312.96m4.38%
Wellington Management Co. LLPas of 31 Mar 202312.06m4.08%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20239.28m3.14%
Massachusetts Financial Services Co.as of 31 Mar 20238.91m3.01%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20238.22m2.78%
Geode Capital Management LLCas of 31 Mar 20236.20m2.10%
Pictet Asset Management SAas of 31 Mar 20235.29m1.79%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 20234.98m1.68%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.